Oral Cancer Screening and Testing
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage rules for oral screening lesion identification systems and genetic/HPV testing related to oral and oropharyngeal cancers for Blue Cross Blue Shield of North Carolina members and providers.
Updated When Covered criteria to allow reimbursement to establish HPV tumor status for oropharyngeal squamous cell carcinoma using either mRNA E6/E7 testing or p16 immunohistochemistry.
Added metastatic squamous cell carcinoma of unknown primary in a cervical lymph node to the When Covered section for HPV testing reimbursement.
Specified detection of HPV from an oropharyngeal swab (e.g., OmniPathology Oropharyngeal HPV PCR Test) is not covered.
Added CPT/HCPCS and other billing codes to the Billing/Coding section including 0296U, 0429U, 81599, 82397, 87624-87626, 88341, 88342.
Coverage Criteria
Coverage for HPV tumor-status testing
Covered when ALL of the following are met
Covered methods include HPV E6/E7 mRNA expression testing or p16 immunohistochemistry (IHC) per guidelines.
HPV testing coverage and investigational screening technologies
Policy stance and coverage rules as reflected in document history and guideline endorsements
Updated language to clarify acceptable test modalities (chunk 30).
Added to When Covered (chunk 30).
Support for clinical contexts where confirmatory HPV‑specific testing is suggested (chunks 18-20).
Historic and recent non‑coverage statements (chunks 29,30).
Reimbursement is not allowed for salivary biomarker testing, HPV genotyping performed on saliva (for example, OraRisk®), gene expression profiling, combined genetic/nongenetic biomarker panels (for example, mRNA CancerDetect™), and detection of HPV from an oropharyngeal swab (for example, OmniPathology Oropharyngeal HPV PCR Test) when used to screen, detect, or diagnose oral cancer.
Oral screening lesion identification systems and genetic screening are not covered for any use. In addition, detection of HPV from an oropharyngeal swab (for example, the OmniPathology Oropharyngeal HPV PCR Test) is explicitly identified as not covered in the policy history and implementation notes.
Routine screening of asymptomatic individuals with swab-based or salivary HPV tests or other adjunctive biomarker tests is not supported by major guideline bodies and therefore is considered not covered for screening purposes. The policy notes that routine swab screening in asymptomatic individuals is not recommended by current cancer guidelines (including CAP) and that USPSTF concluded evidence is insufficient to recommend oral cancer screening in asymptomatic adults.
Historically, oral screening lesion identification systems and genetic screening were considered investigational and not covered beginning with the original policy development (effective 1/1/2019) and through subsequent updates. The policy history documents the investigational stance and additions to the noncovered list over multiple reviews and notices.
Billing and Coding
| No codes listed |
| 81599 | Unlisted multianalyte assay with algorithmic analysis (listed as applicable service code) |
| 82397 | Other chemotherapeutic agent assay (listed as applicable service code) |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA); HPV, high‑risk types, direct probe |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA); HPV, low‑risk types |
| 87626 | Infectious agent detection by nucleic acid (DNA or RNA); HPV, high‑risk types, multiple types (added 1/1/2025) |
| 88341 | Immunohistochemistry, per specimen; initial single antibody stain (p16 IHC applicable) |
| 88342 | Immunohistochemistry, each additional antibody stain |
| 0296U | Proprietary/other molecular test code listed as applicable |
| 0429U | Proprietary/other molecular test code added effective 1/1/2024 |
Provider Actions / Billing Notes
No prior authorization specified
No prior authorization requirement for HPV tumor-status testing or oral cancer screening tests is specified in this policy.
Billing/Coding — codes listed (reimbursement not guaranteed)
The policy lists applicable service codes but states that inclusion does not guarantee reimbursement; prior authorization or medical necessity review may be required per group benefits.
Document diagnosis and testing modality
When reimbursing HPV tumor‑status testing, documentation must support the diagnosis and the clinical context for testing; acceptable testing methods are HPV E6/E7 mRNA expression testing or p16 immunohistochemistry per guidelines.
- Testing covered to establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma or metastatic SCC of unknown primary in a cervical lymph node.
- Covered methods include HPV E6/E7 mRNA expression testing or p16 IHC as indicated by guidelines.
Provide complete medical records on request
BCBSNC may request medical records to determine medical necessity; letters alone are insufficient unless they include all specific information needed for the determination.
- When medical records are requested, letters of support/explanation are often useful but are not sufficient documentation unless they include all specific information needed to make a medical necessity determination.
Documentation to support HPV tumor‑status testing
When reimbursing HPV tumor‑status testing, include documentation that supports oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary in a cervical lymph node; note the policy permits mRNA E6/E7 or p16 IHC modalities.
- Covered indication: OPSCC or metastatic SCC of unknown primary in a cervical lymph node.
- Allowed test modalities: HPV E6/E7 mRNA expression testing or p16 immunohistochemistry.
Medical records required for medical necessity
Retain and provide medical records that demonstrate medical necessity when requested; standalone letters are not sufficient unless they include all required specific clinical details.
- BCBSNC may request medical records for medical necessity determination.
- Letters alone are insufficient unless they contain all specific information needed for the determination.
Denial risk for specified salivary/genetic/swab tests
Claims for salivary biomarker testing, HPV genotyping via salivary tests (for example, OraRisk®), gene expression profiling, panels combining genetic and nongenetic biomarkers (e.g., mRNA CancerDetect™), and detection of HPV from an oropharyngeal swab (e.g., OmniPathology Oropharyngeal HPV PCR Test) will be denied for purposes of screening, detection, or diagnosis of oral cancer.
Oropharyngeal swab HPV tests may be denied
Claims for detection of HPV from an oropharyngeal swab (for example, OmniPathology Oropharyngeal HPV PCR Test) may be denied as not covered.
Reimbursement depends on documentation and medical necessity
Inclusion of a billing code in the Billing/Coding section does not guarantee reimbursement; BCBSNC may request medical records to determine medical necessity and may deny payment if documentation is insufficient.
- Applicable service codes are listed but not a guarantee of reimbursement.
- BCBSNC may request medical records and deny if documentation is insufficient.
Background
Oral cancer — most commonly squamous cell carcinoma — arises in the oral cavity and oropharynx and may be preceded by potentially malignant disorders. Human papillomavirus (HPV) is a major contributor to oropharyngeal squamous cell carcinoma (OPSCC). Conventional oral examination followed by biopsy and histologic evaluation remains the diagnostic standard; adjunctive technologies (vital staining, autofluorescence, brush cytology, salivary/blood biomarkers) have been evaluated but are not replacements for tissue diagnosis.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.